Matches in SemOpenAlex for { <https://semopenalex.org/work/W4211109516> ?p ?o ?g. }
- W4211109516 abstract "Background Dornase alfa is currently used as a mucolytic to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis. It reduces mucus viscosity in the lungs, promoting improved clearance of secretions. This is an update of a previously published review. Objectives To determine whether the use of dornase alfa in cystic fibrosis is associated with improved mortality and morbidity compared to placebo or other medications that improve airway clearance, and to identify any adverse events associated with its use. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and abstracts from conferences. Date of the most recent search of the Group's Cystic Fibrosis Register: 23 April 2018. Clinicaltrials.gov and the International Clinical Trials Registry Platform were also searched to identify unpublished or ongoing trials. Date of most recent search: 07 June 2018. Selection criteria All randomised and quasi‐randomised controlled trials comparing dornase alfa to placebo, standard therapy or other medications that improve airway clearance. Data collection and analysis Authors independently assessed trials against the inclusion criteria; two authors carried out analysis of methodological quality and data extraction. GRADE was used to assess the level of evidence. Main results The searches identified 69 trials, of which 19 (2565 participants) met our inclusion criteria. Fifteen trials compared dornase alfa to placebo or no dornase alfa (2447 participants); two compared daily dornase to hypertonic saline (32 participants); one compared daily dornase alfa to hypertonic saline and alternate day dornase alfa (48 participants); one compared dornase alfa to mannitol and the combination of both drugs (38 participants). Trial duration varied from six days to three years. Dornase alfa compared to placebo or no treatment Dornase alfa improved forced expiratory volume at one second at one month (four trials, 248 participants), three months (one trial, 320 participants; moderate‐quality evidence), six months (one trial, 647 participants; high‐quality evidence) and two years (one trial, 410 participants). Limited low‐quality evidence showed no difference between groups for changes in quality of life. There was a decrease in pulmonary exacerbations with dornase alfa in trials of up to two years (moderate‐quality evidence). One trial that examined the cost of care, including the cost of dornase alfa, found that the cost savings from dornase alfa offset 18% to 38% of the medication costs. Dornase alfa: daily versus alternate day One cross‐over trial (43 children) found no differences between treatment regimens for lung function, quality of life or pulmonary exacerbations (low‐quality evidence). Dornase alfa compared to other medications that improve airway clearance Results for these comparisons were mixed. One trial (43 children) showed a greater improvement in forced expiratory volume at one second for dornase alfa compared to hypertonic saline (low‐quality evidence), and one trial (23 participants) reported no difference in lung function between dornase alfa and mannitol or dornase alfa and dornase alfa plus mannitol (low‐quality evidence). One trial (23 participants) found a difference in quality of life favouring dornase alfa when compared to dornase alfa plus mannitol (low‐quality evidence); other comparisons found no difference in this outcome (low‐quality evidence). No trials in any comparison reported any difference between groups in the number of pulmonary exacerbations (low‐quality evidence). When all comparisons are assessed, dornase alfa did not cause significantly more adverse effects than other treatments, except voice alteration and rash. Authors' conclusions There is evidence to show that, compared with placebo, therapy with dornase alfa improves lung function in people with cystic fibrosis in trials lasting from one month to two years. There was a decrease in pulmonary exacerbations in trials of six months or longer. Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials. There is not enough evidence to firmly conclude if dornase alfa is superior to other hyperosmolar agents in improving lung function." @default.
- W4211109516 created "2022-02-13" @default.
- W4211109516 creator A5004822836 @default.
- W4211109516 creator A5004868297 @default.
- W4211109516 date "2018-09-06" @default.
- W4211109516 modified "2023-10-10" @default.
- W4211109516 title "Dornase alfa for cystic fibrosis" @default.
- W4211109516 cites W175998601 @default.
- W4211109516 cites W177063975 @default.
- W4211109516 cites W1810640413 @default.
- W4211109516 cites W1872952081 @default.
- W4211109516 cites W1960686470 @default.
- W4211109516 cites W1963515595 @default.
- W4211109516 cites W1965385540 @default.
- W4211109516 cites W1968152866 @default.
- W4211109516 cites W1970431627 @default.
- W4211109516 cites W1975609078 @default.
- W4211109516 cites W1975820788 @default.
- W4211109516 cites W1976264709 @default.
- W4211109516 cites W1976867283 @default.
- W4211109516 cites W1978271506 @default.
- W4211109516 cites W1982251574 @default.
- W4211109516 cites W1983495472 @default.
- W4211109516 cites W1991045784 @default.
- W4211109516 cites W1997567908 @default.
- W4211109516 cites W2006292526 @default.
- W4211109516 cites W2006739402 @default.
- W4211109516 cites W2006752980 @default.
- W4211109516 cites W2010678373 @default.
- W4211109516 cites W2023546954 @default.
- W4211109516 cites W2023586232 @default.
- W4211109516 cites W2031789064 @default.
- W4211109516 cites W2036001221 @default.
- W4211109516 cites W2039548615 @default.
- W4211109516 cites W2041807185 @default.
- W4211109516 cites W2045572299 @default.
- W4211109516 cites W2046446743 @default.
- W4211109516 cites W2051130956 @default.
- W4211109516 cites W2054626218 @default.
- W4211109516 cites W2056935354 @default.
- W4211109516 cites W2057510647 @default.
- W4211109516 cites W2059734063 @default.
- W4211109516 cites W2061434168 @default.
- W4211109516 cites W2064024196 @default.
- W4211109516 cites W2070408984 @default.
- W4211109516 cites W2070419306 @default.
- W4211109516 cites W2078078890 @default.
- W4211109516 cites W2096869184 @default.
- W4211109516 cites W2103436692 @default.
- W4211109516 cites W2104379296 @default.
- W4211109516 cites W2107884278 @default.
- W4211109516 cites W2110528741 @default.
- W4211109516 cites W2112485011 @default.
- W4211109516 cites W2113032181 @default.
- W4211109516 cites W2114074118 @default.
- W4211109516 cites W2117530267 @default.
- W4211109516 cites W2118540215 @default.
- W4211109516 cites W2119260499 @default.
- W4211109516 cites W2124135806 @default.
- W4211109516 cites W2125364344 @default.
- W4211109516 cites W2125435699 @default.
- W4211109516 cites W2127136998 @default.
- W4211109516 cites W2128817585 @default.
- W4211109516 cites W2129637598 @default.
- W4211109516 cites W2129756193 @default.
- W4211109516 cites W2129772791 @default.
- W4211109516 cites W2130235475 @default.
- W4211109516 cites W2130690521 @default.
- W4211109516 cites W2132665778 @default.
- W4211109516 cites W2133673354 @default.
- W4211109516 cites W2136652636 @default.
- W4211109516 cites W2144145895 @default.
- W4211109516 cites W2145410540 @default.
- W4211109516 cites W2148217897 @default.
- W4211109516 cites W2150399236 @default.
- W4211109516 cites W2153943794 @default.
- W4211109516 cites W2158898740 @default.
- W4211109516 cites W2161154125 @default.
- W4211109516 cites W2165031309 @default.
- W4211109516 cites W2166747774 @default.
- W4211109516 cites W2172138333 @default.
- W4211109516 cites W2333398204 @default.
- W4211109516 cites W2336714143 @default.
- W4211109516 cites W2414297191 @default.
- W4211109516 cites W4211009199 @default.
- W4211109516 cites W4366305930 @default.
- W4211109516 doi "https://doi.org/10.1002/14651858.cd001127.pub4" @default.
- W4211109516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30187450" @default.
- W4211109516 hasPublicationYear "2018" @default.
- W4211109516 type Work @default.
- W4211109516 citedByCount "57" @default.
- W4211109516 countsByYear W42111095162018 @default.
- W4211109516 countsByYear W42111095162019 @default.
- W4211109516 countsByYear W42111095162020 @default.
- W4211109516 countsByYear W42111095162021 @default.
- W4211109516 countsByYear W42111095162022 @default.
- W4211109516 countsByYear W42111095162023 @default.
- W4211109516 crossrefType "journal-article" @default.
- W4211109516 hasAuthorship W4211109516A5004822836 @default.
- W4211109516 hasAuthorship W4211109516A5004868297 @default.